Atreca, Inc. is a biopharmaceutical company, which is engaged in developing antibody-based immunotherapeutics generated by its differentiated discovery platform. The Company’s platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. The Company’s lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It has demonstrated robust anti-tumor activity as a single agent in multiple preclinical models, including onemodel, in which PD-1 checkpoint inhibitors typically display limited activity. The Company commenced clinical development of ATRC-101 with a Phase Ib clinical trial.